News and releases

SWE adjuvant


Start of COVAC-2 phase 1 clinical trial

Start of COVAC-2 phase 1 clinical trial! A COVID-19 vaccine developed by VIDO which includes the open-access adjuvant Sepivac SWE, co-developed by VFI and Seppic.

Read press release

VIDO’s COVID-19 vaccine receives Health Canada clinical trial approval

VIDO’s COVID-19 vaccine receives Health Canada clinical trial approval for subunit-based vaccine combined to the open-access adjuvant Sepivac SWE, that was developed by Seppic in collaboration with VFI. First-in-human trials are planned in January 2021.

Read press release

The Vaccine Formulation Institute’s squalene-in-water adjuvant SWE is now available from our partner Seppic under the name Sepivac SWE™

Sepivac SWE™ is prepared at cGMP-grade and is being made available to the entire vaccine community under open-access terms. Sepivac SWE™ adjuvant can be used in the composition of several vaccines including vaccines against seasonal influenza, pandemic influenza and COVID-19. A production capacity of several hundred million doses per year of Sepivac SWE™ is expected by summer 2021.

VFI is proud to have co-led the development of the first open-access adjuvant for prophylactic use since aluminium salts in the 1920’s and is grateful to its initial funders (European Commission, US-HHS BARDA and GIZ) for having catalysed the development of the SWE adjuvant. We look forward to continuing this long-term partnership with our Seppic colleagues.

Read Seppic press release

VFI and Seppic announce co-development of a GMP emulsion-based adjuvant for human prophylactic vaccines (including COVID-19 vaccines) on an open-access basis

VFI and Seppic announced that they have finalized the development of an oil-in-water adjuvant at a Seppic plant in France. The adjuvant, manufactured under Good Manufactured Practices, will be openly available from Seppic before the end of this year, for the entire vaccine community.

Read press release